Europe Soft Tissue Sarcoma Market to Witness Substantial Growth through 2025
Growing pool of patients
suffering from sarcoma and increasing adoption of novel therapeutics to drive
the growth of Europe soft tissue sarcoma market
According
to TechSci Research report, “Europe Soft Tissue Sarcoma Market By Treatment (Targeted Therapy,
Chemotherapy, Anti-Angiogenesis Drug, Radiation Therapy), By Disease Type
(Local Sarcoma, Regional Sarcoma, Metastatic Sarcoma), By End User (Hospitals,
Oncology Center, Long Term Care Center), By Country, Forecast &
Opportunities, 2025”, the market is anticipated to
witness significant growth during the forecast period owing to the increase in
funding by European Union for research and development to find cure and
effective therapies for soft tissue sarcoma. The region is witnessing an
increasing pool of patients suffering from this disease which is also acting as
a major factor for the market growth. Also, growing awareness among people
about soft tissue sarcoma and increasing per capita disposable income of
customers are some other factors which are expected to support the growth of
this market until 2025.
Additionally, Europe is witnessing a substantial
increase in the approval for manufacture of generic drugs, which is serving as
a major growth factor for soft tissue sarcoma market. On top of that, rise in
quality patient care and patent expiry of branded drugs is encouraging more
companies to enter the market. Moreover, manufacturers are engaging in extensive
R&D activities to find advanced treatments such as targeted and biological
therapies. Furthermore, with prevalence of around 50 different types of
sarcomas, there is a growing need for better treatment in the region. Hence,
all these factors are expected to drive the growth of Europe soft tissue sarcoma
market over the coming years.
However, the market might also face some restraints
such as adverse side effects and high cost of therapies. Also, stringent
regulatory guidelines by the government might limit the growth of soft tissue
sarcoma market in Europe.
Browse
XX market data Tables and XX Figures spread through XXX
Pages and an in-depth TOC on "Europe Soft Tissue Sarcoma Market"
https://www.techsciresearch.com/report/europe-soft-tissue-sarcoma-market/4852.html
The Europe
soft tissue sarcoma market is segmented based on treatment, disease type, end
user and region. Based on end user, the market is divided into hospitals,
oncology center, long term care center. Among these, the oncology centers
segment is anticipated to witness rapid growth during he forecast period as the
region is witnessing rise in number of such centers. Moreover, the availability
of such specialized centers to treat cancer-based diseases such as soft tissue
sarcoma, etc., is attracting more patients to undertake the treatment, thereby
fueling the market.
Based
on treatment, the Europe soft tissue sarcoma market is segmented into targeted
therapy, chemotherapy, anti-angiogenesis drug and radiation therapy. Out of
these, the chemotherapy segment currently dominates the market owing to its
high success rate in terms of treatment. Additionally, the treatment uses a
combination of various anti-cancer drugs and has high success rate compared to
other cancer treatments. However, targeted therapy is expected to witness rapid
growth during the forecast period owing to its superior efficacy and increasing
adoption of novel therapeutics.
Major players operating in the Europe soft
tissue sarcoma market include GlaxoSmithKline PLC, Eli Lilly Italia - S.P.A.,
Pfizer Deutschland GmbH., Bristol-Myers Squibb SARL, F. Hoffmann-La Roche AG,
Teva Pharmaceuticals Europe BV, Celgene Europe Ltd, Zimmer GmbH, RTI UK Ltd,
MiMedx and Integra LifeSciences Services France SASU. The companies are
investing in extensive R&D activities to develop more effective treatments
and drugs to treat soft tissue sarcoma. Some players are also engaging in
partnerships and mergers to increase their market share.
Download
Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4852
Customers can also request for 10% free
customization on this report.
“Soft
tissue sarcoma is a rare type of cancer and countries such as Germany and Italy
are witnessing spike in number of patients suffering from these diseases. The
recent approval of drugs like Eisai’s Halaven, which are used in chemotherapy,
are boosting the market growth and the region is also witnessing entry of
several new pharmaceutical manufacturers. With European Union’s focus to invest
more on healthcare, the region is anticipated to emerge as a favorable market
for companies dealing in medications for treating soft tissue sarcoma ,” said
Mr. Karan Chechi, Research Director with TechSci Research, a research based global
management consulting firm.
“Europe Soft Tissue Sarcoma Market By Treatment
(Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug, Radiation Therapy), By
Disease Type (Local Sarcoma, Regional Sarcoma, Metastatic Sarcoma), By End User
(Hospitals, Oncology Center, Long Term Care Center), By Country, Forecast &
Opportunities, 2025” has
evaluated the future growth potential of Europe soft tissue sarcoma market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges and opportunities in Europe soft tissue sarcoma market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]